Johnson & Johnson’s Q1 profit rises 8 pct on lower spending, surge in prescription drug sales

NEW BRUNSWICK, N.J. – Johnson & Johnson says its first-quarter profit rose 8 per cent, because of restrained costs and a big jump in prescription drug sales. The world’s biggest maker of health care products easily beat Wall Street expectations and raised its earnings outlook.

The maker of Tylenol, medical devices and prescription drugs said Tuesday that net income was $4.73 billion, or $1.64 per share, up from $3.5 billion, or $1.22 per share, a year earlier.

Excluding one-time items, income was $4.43 billion, or $1.54 per share. Analysts surveyed by FactSet expected $1.48.

Revenue totalled $18.12 billion, up 3.5 per cent. Analysts expected $18.04 billion.

The company, based in New Brunswick, N.J., raised its profit forecast for 2014 to $5.80 to $5.90 per share. In January, J&J forecast $5.75 to $5.85.

News from © The Associated Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

The Associated Press

The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world’s population sees AP journalism every day.